RxDoctor Payments DataLook up a doctor →

Jerome Daniel, MD

Family Medicine · North Chesterfield, VANPI 1790770329

Payments from drug & device makers

$779,028in general payments, 2019–2025

Across 733 payments — averaging $1062.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$271K
  • Pfizer$169K
  • Sanofi US Services Inc.$89K
  • AstraZeneca$83K
  • Cipla USA Inc.$71K
  • Merck$36K
  • plus $59K from 43 others
$2,491in research payments, 2019–2025

Across 1 payment — averaging $2490.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

What the payments were for

  • Travel & lodging$1,08114%
  • Food & beverage$6,77886%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$779,028 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$116,945
Medicare patients
439
Services billed
2,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate59$87,897
EliquisApixaban27$39,968
XareltoRivaroxaban27$29,449
JanumetSitagliptin Phos/Metformin Hcl13$20,066
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$15,977
JardianceEmpagliflozin24$15,615
FarxigaDapagliflozin Propanediol11$11,626
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$8,017
SymbicortBudesonide/Formoterol Fumarate16$7,567
Gabapentin201$3,534
Nebivolol Hcl35$3,067
Simvastatin290$2,554
Metoprolol Succinate162$2,495
Atorvastatin Calcium300$2,479
Levothyroxine Sodium212$2,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$35,720$107,96372 claims
PfizerEliquis$169,003$39,96827 claims
Johnson & JohnsonXarelto$11$29,44927 claims
AstraZenecaFarxiga, Symbicort$83,445$19,19327 claims
Boehringer IngelheimJardiance$252$15,61524 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$22$2,317212 claims
AbbVieSynthroid$270,721$1,19126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in North Chesterfield

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →